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Summary
Depressed patients have reduced glucocorticoid receptor (GR) function, as demonstrated by
resistance to the suppressive effects of the synthetic glucocorticoid hormone, and GR agonist,
dexamethasone. We have developed a suppressive test with prednisolone, a synthetic
glucocorticoid that is similar to cortisol in its pharmacodynamics and pharmacokinetics, and binds
to both the GR and the mineralocorticoid receptor (MR). We have found that depressed patients
suppress normally to prednisolone, unless they are particularly non-responsive to treatment. In the
present study, we evaluated 28 inpatients with treatment-resistant depression (TRD), and
compared salivary cortisol secretion (at 0900 h, 1200 h and 1700 h) after placebo or after
prednisolone (5 mg), before and after an inpatient treatment admission. Half of the patients (n =
14) reached treatment response. When comparing the assessment between admission and
discharge, cortisol output after placebo fell (−26% of area under the curve; p = 0.024) while the
output after prednisolone did not change. Moreover, there was no change in the response to
prednisolone (percentage suppression) between admission at discharge, and this was not
influenced by treatment response. Finally, we could confirm and extend our previously published
data with prednisolone (5 mg), showing that depressed patients (n = 12) and controls (n = 12)
suppressed equally to both 5 and 10 mg doses of prednisolone. This study suggests that the
response to prednisolone is similar in depressed patients and controls at different doses of
prednisolone, and does not change with symptomatic improvement. This is in contrast with
findings, from us and others, using other measures of hypothalamic—pituitary—adrenal axis
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function, such as basal cortisol levels or the response to dexamethasone. Thus, we propose that the
prednisolone suppression test may offer specific biological and clinical information, related to its
action at both the GR and the MR.
Keywords
Cortisol; Depression; Glucocorticoid receptor; Hypothalamic—pituitary—adrenal (HPA) axis;
Mineralocorticoid receptor; Prednisolone; Negative feedback; Treatment-resistant depression
1. Introduction
We have recently developed a novel suppressive test for the hypothalamic—pituitary—
adrenal (HPA) axis, using the synthetic glucocorticoid prednisolone (Pariante et al., 2002,
2004; Juruena et al., 2006, 2009b). Compared to dexamethasone, used in the more
traditional dexamethasone suppression test (DST) and dexamethasone/corticotrophin
releasing hormone (DEX/CRH) test, prednisolone mimics more closely the pharmacological
profile of the endogenous glucocorticoid, cortisol. In fact, whilst dexamethasone only probes
the function of the “low-affinity” cortisol receptor (glucocorticoid receptor, or GR),
prednisolone probes both GR and the “high-affinity” cortisol receptor (mineralocorticoid
receptor, or MR). Furthermore, the half-life of prednisolone is also similar to that of cortisol,
while dexamethasone has a 2—4-fold longer half-life (Orth and Kovacs, 1998). Therefore,
the prednisolone test has been proposed as a more naturalistic test for the HPA axis to be
used in biological psychiatry (Pariante et al., 2002, 2004; Juruena et al., 2006, 2009b).
Our research in depressed inpatients has indeed shown that the HPA axis response to
prednisolone is different from the response to dexamethasone: that is, depressed patients
tend to show impaired HPA axis suppression by dexamethasone, indicating impaired GR
function, but normal HPA axis suppression by prednisolone (Juruena et al., 2006). We have
interpreted these findings as suggesting an intact or even increased MR function,
compensating for the impaired GR. Indeed, these results and their interpretation are
consistent with a study by Young et al., who assessed MR function using an MR antagonist,
spironolactone (Young et al., 2003), and also found intact response in depressed patients.
Interestingly, the DEX/CRH test is considered a “state” marker in depression, with studies
showing normalization of the cortisol response to DEX/CRH challenge after successful
antidepressant treatment (Ising et al., 2007). We have recently shown that, although the
response to prednisolone is overall normal in depressed patients, a subgroup of patients who
will later fail to respond to an inpatient therapeutic package does show impaired response to
prednisolone (Juruena et al., 2009b). In the present study, we describe the prospective
changes in the prednisolone suppression test before and after receiving the intensive
inpatient therapeutic package, and their relationship with the clinical improvement.
Finally, our studies have been conducted using a “low” dose (5 mg) of prednisolone, leading
to approximately 40% suppression of cortisol production in normal individuals the following
day; in contrast, dexamethasone 0.5 mg, for example, leads to approximately 85%
suppression of cortisol production in normal individuals the following day (Pariante et al.,
2002; Juruena et al., 2006). In the present study, we also describe the effects of two different
doses of prednisolone (5 and 10 mg) in depressed patients and matched controls.
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2. Methods
The study utilized a single-blind, non-randomized, placebo-controlled, repeated measure
design, as previously described (Pariante et al., 2002, 2004; Juruena et al., 2006, 2009b).
Briefly, on Day 1, 28 depressed inpatients received placebo capsules, and on Day 2 they
received 5 mg prednisolone capsules, both at 2200 h. No alcohol, coffee, tea or meals were
allowed after each capsule. On the day following each capsule administration, saliva
samples were collected at 900 h, 1200 h and 1700 h. The test was administered shortly after
admission (range 5—21 days), and then repeated before discharge, after an median of 21
weeks of inpatient stay (range 6—57 weeks).
Twelve depressed subjects also received 10 mg of prednisolone on Day 3, at least 48 h after
Day 2, again at 2200 h. Twelve healthy controls also received prednisolone 10 mg. Subjects
were then assessed as above.
Patients in this study belong to a larger sample (n = 45) who completed the test at baseline,
as recently described (Juruena et al., 2009b), and were all inpatients on the National
Affective Disorders Unit (ADU) of the Bethlem Royal Hospital (South London and
Maudsley NHS Trust). Both the clinical assessment and the therapeutic intervention have
been extensively described before (Fekadu et al., 2009; Juruena et al., 2009b). Briefly, they
were all diagnosed as having unipolar major depressive disorder according to the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition — DSM-IV (American
Psychiatric Association, 1994), using the Structured Clinical Interview for DSM-IV Axis I
disorders (SCID-I) (First et al., 1997). In addition, all patients were treatment resistant on
the basis of prior non-response to at least two different classes of antidepressants, as
assessed by the Antidepressant Treatment History Form (Sackeim et al., 1990). The degree
of treatment resistance was staged according to the criteria of Thase and Rush (1997). For
clinical severity of depression, we used the 21-item Hamilton Rating Scale for Depression
(HAMD-21) (Hamilton, 1960). The therapeutic intervention consisted of an individualised
combination of the following therapies as clinically indicated for each patient: (1) intensive
psychopharmacology utilising combinations of medications as guided by the Maudsley
Prescribing Guidelines (Taylor et al., 2005); (2) weekly cognitive behavioural therapy; (3)
daily occupational therapy; (4) fortnightly couple therapy; (5) alleviation of any physical
health consequences or corollaries of depression (such as hypercholesterolaemia,
hypertension, obesity, malnutrition and dental problems); and (6) supportive and enabling
nursing care including group sessions for anxiety management and behavioural activation
(Juruena et al., 2010). Patients’ response to treatment was carefully assessed by repeating
shortly before discharge the same psychometric measures that were administered at baseline.
Response was defined as a reduction of HAMD-21 score of 50% or greater, while remission
was defined as reduction HAMD-21 score to 7 or below. Exclusion criteria for the study
were: a history of hypersensitivity to corticosteroids or steroid use; heavy smokers (more
than 25 cigarettes/day); viral illnesses during the preceding 2 weeks; pregnant or lactating
women; alcohol dependence; and significant physical illnesses (for example, severe
allergies, autoimmune diseases, hypertension, malignancy, haematological, endocrine,
pulmonary, renal, hepatic, gastrointestinal, or neurological disease). Patients with bipolar
affective disorder, psychotic symptoms unrelated to their depressive disorder, or an organic
aetiology were excluded. The study protocols were all approved by the Research Ethical
Committee of the Institute of Psychiatry and South London and Maudsley NHS Trust.
Written informed consent was obtained from all subjects. Healthy controls were recruited
from hospital staff, students and the local community. The 12 patients and 12 controls who
received prednisolone 10 mg were matched according to age (to within a limit of 5 years),
gender and body mass index (BMI; within a range of ±5kg/m2).
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The protocol for the salivary collection has been described before (Pariante et al., 2002,
2004; Juruena et al., 2006, 2009b). Both patients and controls were admitted to the research
rooms of the ADU, where they spent the period 0845—1715 h engaged in sedentary
activities. Snacks, meals and drinks were standardized throughout the day. Saliva samples
were collected using Salivettes (Sarstedt, Leicester, UK), and cortisol concentrations
measured using a time-resolved immunofluorescent assay (TR-FIA), as previously described
(Juruena et al., 2009b, 2010).
Plasma levels of prednisolone (from samples collected at 9:00 the following morning) were
measured by high performance liquid chromatography (Hewlett-Packard UV Detector
linked to Chemstation collection system), again as previously described (Juruena et al.,
2009b).
The general linear model (GLM) analysis for repeated measures was used to examine
within-group differences (admission vs. discharge) in cortisol levels after placebo and
prednisolone. As previously described, we also used as summary measures the total salivary
cortisol output, calculated as the area under the curve (AUC) using the trapezoidal method,
after placebo and prednisolone, and further calculated the percentage suppression of salivary
cortisol for each individual. The latter is a measure of suppression that is independent of the
absolute cortisol levels (Pariante et al., 2002, 2004; Juruena et al., 2006, 2009b, 2010). We
used t tests (paired, when appropriate) to compare clinical data, AUC values, percentage
suppression, and prednisolone plasma levels, between admission and discharge, or patients
and controls (for the 10 mg only). All values are presented as means (and ± standard error of
the mean [SEM]).
3. Results
The sample included 21 females (75%), and had a mean age of 51.5 (±10.3) years. Twenty-
three were taking medication, while five (18%) were drug free for at least 14 days before
placebo and prednisolone challenge. All the remaining were receiving either a selective
serotonin reuptake inhibitor or a serotonin and noradrenaline (non-tricyclic) reuptake
inhibitor, often in combination with a mood stabilizer (n = 20). Further clinical details are
described in Table 1.
The HAMD-21 mean scores were 25.2 (±1.0) at admission and 16.5 (±1.5) at discharge.
Although the overall decrease in HAMD-21 was significant (t = 5.3, df = 27, p < 0.001),
only half of the patients (n = 14) reached treatment response, and a quarter (n = 7) reached
remission. This was not unexpected, as they all qualified as a previously treatment-resistant
population.
The cortisol levels after placebo and the prednisolone suppression test were conducted at the
beginning of the inpatient treatment, and shortly before discharge. The GLM analysis tested
the differences between admission and discharge, separately for placebo and prednisolone,
using the individual cortisol levels measured at 900 h, 1200 h and 1700 h (see Fig. 1).
The results show that cortisol levels output after placebo, but not after prednisolone,
changed significantly between admission and discharge. Cortisol levels after placebo
decreased between admission and discharge by approximately 26% of cortisol output (F =
5.4, df = 1, 54; p = 0.024). However, there was no difference in cortisol levels output after
prednisolone between admission and discharge (F = 1.3, df = 1, 54; p = 0.3).
More importantly, when we tested the ability of prednisolone to suppress the HPA axis at
admission and discharge, using the percentage suppression, we found no changes in the
sensitivity to prednisolone. Indeed, there was a small and not significant reduction in the
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percentage suppression (that is, patients becoming less sensitive): −35.4% (±6.7) at
admission vs. −27.1% (±6.8) at discharge (t = − 1.1; df = 27; p = 0.3).
Interestingly, the change in percentage suppression was not influenced by treatment
response, as shown in Fig. 2. We have previously described (in a larger sample, including
the patients presented here) that the suppressive response to prednisolone is impaired in
patients who subsequently fail to respond to our inpatient therapeutic package (Juruena et
al., 2009b). Also in this subsample we found that the response to prednisolone at admission
was impaired in subsequent nonresponders vs. responders (approximately −27% vs. −44%).
However, this response did not change between admission and discharge, in either of the
two groups: approximately −27% at admission vs. −21% at discharge in non-responders (t =
−0.8; df = 13; p = 0.45) and −44% at admission vs. −33.5% at discharge in responders (t =
−0.8; df = 13; p = 0.4) (see Fig. 2). Also, there were no changes in prednisolone plasma
levels between admission and discharge: 34.1 (±5.8) ng/ml at admission vs. 29.1 (±5.6) ng/
ml at discharge (t = 0.6; df = 27; p = 0.5).
Finally, the dose—response study shows that depressed patients and controls suppressed
equally to both the low and the high doses of prednisolone, as shown in Fig. 3. The
percentage suppression was approximately vs. −40% in patients −50% in controls after 5 mg
(t = −1.1; df = 22; p = 0.3), and −59% in patients vs. −69% in controls (t = 0.9; df = 22; p =
0.4) after 10 mg of prednisolone (see Fig. 3). As expected, prednisolone plasma levels were
higher after the 10 mg than after the 5 mg dose, both in patients and controls: 66.5 (±10.9)
ng/ml after 5 mg vs. 85.5 (±10.2) ng/ml after 10 mg in patients (t = −2.8; df = 11; p = 0.02),
and 56.1 (±5.1) ng/ml after 5 mg vs. 90.9 (±10.1) ng/ml in controls (t = −2.9; df = 11; p =
0.015).
4. Discussion
We present here two separate but complementary studies bringing additional information on
the prednisolone suppression test in patients with treatment-resistant depression. First, the
response to prednisolone does not change before and after an inpatient therapeutic
intervention, even in those who respond to treatment. Second, as we have previously
demonstrated for the lower (5 mg) dose (Juruena et al., 2006, 2009b), the higher (10 mg)
dose of prednisolone also suppresses equally cortisol levels in patients and controls.
We have previously argued that the prednisolone suppression test, differently from the DST
and the DEX/CRH test, probes both the MR and the GR (Juruena et al., 2006, 2009b).
Indeed, in a previous study comprising 18 of the 28 subjects of this study, we found that
patients with major depression tend to have a normal response to prednisolone even in the
presence of an impaired (GR-mediated) response to dexamethasone (Juruena et al., 2006).
Specifically, in the previous study we administered dexamethasone (0.5 mg), and found, as
expected, an impaired suppression by dexamethasone: cortisol output during the day was
decreased by 85% in controls but only by 46% in depressed patients (an effect size
difference of d = 1.6). However, the same depressed patients showed normal suppression by
prednisolone (5 mg): suppression was −41% in controls and −36% in depressed patients
(Juruena et al., 2006). This theoretical framework is consistent with studies assessing MR
function and MR expression in depression and bipolar illness, that also found no difference
between patients and controls (Lopez et al., 1998; Young et al., 2003; Juruena et al., 2009a).
Moreover, the current study confirms and extends our published findings, not only by
replicating, in a new sample, similar suppression by prednisolone 5 mg in patients and
controls, but also by showing similar suppression by prednisolone 10 mg.
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We have also previously found that a subgroup of highly resistant depressed patients does
show an impaired response to prednisolone, and this is indeed associated with a lack of
future response to an inpatient treatment package (Juruena et al., 2009b, 2010). A subset of
this sample is described here, and again we were able to show this difference (approximately
17%) which is almost identical to the difference in the larger published sample
(approximately 21%). This paper extends these findings by demonstrating that the response
to prednisolone is stable, and does not change with symptomatic improvement. Indeed, it
might be considered surprising that the response to prednisolone changed little between
admission and discharge, considering that this is an inpatient unit where the subjects
received an intense clinical package, including optimisation of pharmacological treatment as
well as psychotherapeutic intervention. This lack of change in the response is in contrast
with the clear improvement in depressive symptoms that these subjects showed overall, and
is not influenced by whether subjects did or did not respond to treatment at the time of their
discharge. Of note is also that subjects did show changes in other aspects of the HPA axis
(i.e., reduction in cortisol production during the day). Other studies have also shown that the
response to the DEX/CRH test changes with symptomatic improvement (Ising et al., 2007).
It is the response to prednisolone that seems to remain unchanged.
Based on our findings, we would speculate that MR function (as measured by the response
to prednisolone) is a stable aspect of HPA axis activity, which does not change, in depressed
subjects, with improvement in symptoms. Therefore, an abnormal MR function (as
measured by an impaired response to prednisolone) could be considered a stable biomarker
of poor clinical course and lack of response to treatment. Indeed, the notion that effective
MR functioning is required for therapeutic response in depression is supported also by
studies showing that MR blockade worsens depressive symptoms (Holsboer, 1999) and that
MR stimulation improves response to treatment (Otte et al., 2010). Alternatively, the lack of
changes in the response to prednisolone may be explained by the specific features of this
clinical sample. First of all, being a treatment-resistant group, this sample had low rates of
response (50%) and remission (25%). Improvement in the HPA axis response to DEX/CRH
in previous studies is particularly evident in those who reach remission at discharge (Binder
et al., 2009) and therefore our sample may simply not have improved enough to show
relevant biological changes in HPA axis function. Moreover, patients with bipolar or
psychotic depression show a lack of normalisation of the DEX/CRH test even in the
presence of improvement in depressive symptoms (Owashi et al., 2008; Hennings et al.,
2009; Juruena et al., 2009a); although bipolar patients were excluded from the study sample,
this is a particularly severe treatment-resistant sample, and some patients had mood-
congruent psychotic symptoms. Finally, normalisation of the HPA axis activity occurs as
early as the first 1—2 weeks of antidepressant treatment, and some studies have shown that
a longer duration of admission is associated with an increase, rather than a decrease, of HPA
axis activity (Zobel et al., 1999). Since the average duration of admission in our subjects
was 21 weeks, it is possible that patients exhibited a degree of this “late increase” before
being retested. Indeed, this late increase in HPA response to DEX/CRH at discharge is a
predictor of future (within the following 6 months) relapse (Zobel et al., 1999), and our
clinical population is also at a high risk of relapsing and/or of remaining continuously ill
(Fekadu et al., 2009).
In summary, and notwithstanding the clear limitation of the small sample size, this study is
the first in which the prednisolone suppression test has been repeated after treatment, and
adds to the mounting evidence that this novel challenge may probe different aspects of the
HPA axis compared to the classic DST and DEX/CRH test.
Juruena et al. Page 6
Psychoneuroendocrinology. Author manuscript; available in PMC 2012 December 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Acknowledgments
We acknowledge the support of the staff of the National Affective Disorders Unit in undertaking this research.
Role of the funding sources
This research has been supported by a 2003 and a 2005 NARSAD Young Investigator Award, and a 2004—2009
MRC Clinician Scientist Fellowship, to C.M. Pariante; by a 2003 CAPES Fellowship Award, a 2006 NARSAD
Young Investigator Award and a 2007—2009 FAPESP Postdoctoral Fellowship Award to M.F. Juruena; and by the
NIHR Biomedical Research Centre at South London and Maudsley NHS Trust & Institute of Psychiatry (Kings’
College London). None of the funding sources played any further role in study design; in the collection, analysis
and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
References
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American
Psychiatric Press; Washington, DC: 1994.
Binder EB, Kunzel HE, Nickel T, Kern N, Pfennig A, Majer M, Uhr M, Ising M, Holsboer F. HPA-
axis regulation at in-patient admission is associated with antidepressant therapy outcome in male
but not in female depressedpatients. Psychoneuroendocrinology. 2009; 34:99–109. [PubMed:
18829172]
Fekadu A, Wooderson SC, Markopoulou K, Cleare AJ. The MaudsleyStaging Method for treatment-
resistant depression: prediction of longer-termoutcome and persistence of symptoms. J. Clin.
Psychiatry. 2009; 70:952–957. [PubMed: 19457299]
First, MB.; Spitzer, RL.; Gibbon, M.; Williams, JBW. Structured ClinicalInterview for DSM-IV Axis I
Disorders—Clinician Version (SCID-CV). American Psychiatric Press; 1997.
Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960; 23:56–62.
[PubMed: 14399272]
Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, Dose T, Wollweber B,
Spieler D, Messer T, Lutz R, Kunzel H, Bierner T, Pollmacher T, Pfister H, Nickel T, Sonntag A,
Uhr M, Ising M, Holsboer F, Lucae S. Clinical characteristics and treatment outcome in a
representative sample of depressed inpatients—findings from the Munich Antidepressant Response
Signature (MARS) project. J. Psychiatr. Res. 2009; 43:215–229. [PubMed: 18586274]
Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat
depression and anxiety. J. Psychiatr. Res. 1999; 33:181–214. [PubMed: 10367986]
Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N, Kunzel HE, Pfennig A, Uhr M,
Holsboer F. Combined dexamethasone/corticotropin releasing hormone test predicts treatment
response in major depression—a potential biomarker? Biol. Psychiatry. 2007; 62:47–54. [PubMed:
17123470]
Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM. Different responses to
dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl.).
2006; 189:225–235. [PubMed: 17016711]
Juruena MF, Gama CS, Berk M, Belmonte-de-Abreu PS. Improved stress response in bipolar affective
disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. J.
Psychopharmacol. 2009a; 23:985–987. [PubMed: 18583441]
Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ. Prednisolone
suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment
resistance. Br. J. Psychiatry. 2009b; 194:342–349. [PubMed: 19336786]
Juruena MF, Pariante CM, Papadopoulos A, Cleare AJ. The Development and Application of the
Prednisolone suppression Test in Psychiatry: A novel Tool for Assessing Glucocorticoid and
Mineralocorticoid Receptor Function. Mind & Brain, J. Psych. 2010; 1(1):115–122.
Lopez JF, Chalmers DT, Little KY, Watson SJ. A. E. Bennett Research Award. Regulation of
serotonin 1A, glucocorticoid, and mineralocorticoidreceptor in rat and human hippocampus:
implications for the neurobiology of depression. Biol. Psychiatry. 1998; 43:547–5732. [PubMed:
9564441]
Juruena et al. Page 7
Psychoneuroendocrinology. Author manuscript; available in PMC 2012 December 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Orth, D.; Kovacs, W. The adrenal cortex. In: Wilson, J.; Foster, D.; Kronenberg, H.; Larsen, P.,
editors. Williams Textbook of Endocrinology. W.B. Saunders Company; Philadelphia: 1998. p.
517-664.
Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, Kellner M. Modulation of the
mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind,
placebo-controlled proof-of-concept study. J. Psychiatr. Res. 2010; 44(6):339–346. [PubMed:
19909979]
Owashi T, Otsubo T, Oshima A, Nakagome K, Higuchi T, Kamijima K. Relationships of DEX/CRH
and GHRH test results to the outcome of depression—preliminary results suggest the GHRH test
may predict relapse after discharge. J. Psychiatr. Res. 2008; 42:356–364. [PubMed: 17412362]
Pariante CM, Papadopoulos AS, Poon L, Checkley SA, English J, Kerwin RW, Lightman S. A novel
prednisolone suppression test for the hypothalamicpituitary—adrenal axis. Biol. Psychiatry. 2002;
51:922–930. [PubMed: 12022966]
Pariante CM, Papadopoulos AS, Poon L, Cleare AJ, Checkley SA, English J, Kerwin RW, Lightman
S. Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy
volunteers. Psychopharmacology (Berl.). 2004; 177:200–206. [PubMed: 15179544]
Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance
and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in
major depression. J. Clin. Psychopharmacol. 1990; 10:96–104. [PubMed: 2341598]
Taylor, D.; Paton, C.; Kerwin, R. The South London and Maudsley NHS Trust Oxleas NHS Trust,
Prescribing Guidelines. 8th ed.. Taylor & Francis; London: 2005.
Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant
nonresponders. J. Clin. Psychiatry. 1997; 58(Suppl. 13):23–29. [PubMed: 9402916]
Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. Mineralocorticoid receptor function in
major depression. Arch. Gen. Psychiatry. 2003; 60:24–28. [PubMed: 12511169]
Zobel AW, Yassouridis A, Frieboes RM, Holsboer F. Prediction of medium-term outcome by cortisol
response to the combined dexamethasone-CRH test in patients with remitted depression. Am. J.
Psychiatry. 1999; 156:949–951. [PubMed: 10360139]
Juruena et al. Page 8
Psychoneuroendocrinology. Author manuscript; available in PMC 2012 December 04.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1.
Cortisol output levels between 0900 h and 1700 h in a sample (n = 28) of depressed
inpatients with treatment-resistant depression (TRD), at admission (circles) and discharge
(squares), after placebo (continuous line) and prednisolone (5 mg; dashed line). A general
linear model analysis for repeated measures was used to examine within-group differences
(admission vs. discharge) in cortisol levels after placebo and prednisolone. Cortisol levels
after placebo fall significantly between admission and discharge, but not cortisol levels after
prednisolone.
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Figure 2.
Cortisol output, measured as percentage area under the curve relative to placebo, in a sample
of depressed inpatients (n = 28) after placebo and prednisolone (5 mg), at admission and
discharge. The response to prednisolone did not change in either patients who subsequently
responded to treatment (n = 14; in gray) or patients who did not respond (n = 14; in black).
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Figure 3.
Cortisol output, measured as percentage area under the curve relative to placebo, in a sample
of depressed inpatients (n = 12; black) and matched controls (n = 12, gray) after placebo,
prednisolone (5 mg), and prednisolone (10 mg). The dose—response study shows that
depressed patients and controls suppressed equally to both the low and the high doses of
prednisolone.
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Table 1
Demographics and clinical features of treatment-resistant depression patients (TRD), whole sample n = 28.
Mean (SEM) or n (%)
Treatment-resistant
depression (n = 28)
Gender (%) 21 f (75%)
Age (y) 51.5 (2.0)
BMI (Kg/m2) 29.3 (1.0)
Current medication (%) SSRI/SNRI 23 (82%)
Mood stabilizer 20 (71%)
Other(s) clinical
medications 17 (60%)
Benzodiazepine 16 (57%)
Atypical antipsychotic
11 (29%)
Tricyclic antidepressant
7 (20%)
MAOI 5(18%)
Drug free 5 (18%)
Other antipsychotic
2 (07%)
ECT in the past (%) 22 (79%)
TRD stage: n (%) Stage 5: 23 (82%)
Stage 4: 01(4%)
Stage 3: 04 (14%)
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